ReviewJournal of cardiothoracic surgery2026
Pulmonary metastasectomy: a 14-year single-center experience and literature review.
Review in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary metastasectomy (PM) is a commonly performed surgical procedure in selected patients with metastatic disease. The characteristics of patients undergoing PM and the spectrum of primary malignancies considered for surgical resection vary across institutions. We aim to provide a better understanding of current practice patterns by describing the characteristics and perioperative outcomes of patients who underwent PM at our institution.
methodsWe conducted a retrospective descriptive study of patients who underwent pulmonary metastasectomy between 2008 and 2022 at Ghaem Hospital, Mashhad, Iran. Demographic and clinicopathological data, including age, sex, primary tumor type, histology, and postoperative outcomes, were collected and analyzed.
resultsA total of 128 patients (mean age, 38.9 ± 18.0 years) were included in the analysis. The most common primary tumor sites were bone (25.8%) and soft tissue (16.4%), followed by head and neck (9.4%), colorectal (7.0%), and testicular (7.0%) malignancies. Sarcoma was the predominant histologic subtype (57.8%), followed by squamous cell carcinoma (11.7%), adenocarcinoma (10.9%), and germ cell tumors (7.8%). Postoperative complications included air leakage (n = 35), vascular injury requiring blood transfusion (n = 34), and one surgical site infection.
conclusionPulmonary metastasectomy is performed in patients with a wide range of primary malignancies, with sarcoma representing the most common indication in our cohort. Review of the literature suggests that the role of pulmonary metastasectomy varies across different primary malignancies and depends on careful patient selection. Further prospective studies are needed to better define the clinical utility of pulmonary metastasectomy in different tumor types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.